Skip to main content Skip to main navigation menu Skip to site footer

Pre-exposure prophylaxis (PrEP) pada pencegahan human immunodeficiency virus (HIV) dan dampaknya terhadap infeksi menular seksual

  • Pande Agung Mahariski ,
  • Ni Made Dwi Puspawati ,
  • I Gusti Ayu Agung Elis Indira ,
  • I Gusti Ayu Agung Praharsini ,
  • Aditya Permana ,


As part of a comprehensive strategy to prevent human immunodeficiency virus (HIV) infection, pre-exposure prophylaxis (PrEP), safe sex practices, routine HIV testing, HIV risk reduction counseling, and consistent and correct use of condoms are largely effective in HIV prevention. Pre-exposure prophylaxis is intended for people who engage in high-risk sexual behavior and do not use condoms consistently. The use of PrEP is widely promoted in the man who have sex with men (MSM) community, including MSM who wish to practice safer sex in sexual relationships with casual partners who have difficulty sharing HIV status and sexually transmitted infections (STIs) with sexual partners. However, due to the inconsistent practice of using condoms when using PrEP, there is an impact, namely an increase in the incidence of other sexually transmitted infections. In addition to the increased transmission of disease, especially bacterial infections, PrEP also has a protective effect against the herpes simplex virus (HSV). This literature review discusses PrEP and its impact on sexually transmitted infections.



Sebagai bagian dari strategi pencegahan komprehensif infeksi human immunodeficiency virus (HIV), penggunaan pre-exposure prophylaxis (PrEP) disertai praktik seks aman, tes HIV rutin, konseling pengurangan risiko HIV, dan penggunaan kondom yang konsisten dan benar sebagian besar efektif terhadap pencegahan HIV. Pre-exposure prophylaxis ditujukan untuk orang yang melakukan perilaku seksual berisiko tinggi dan tidak menggunakan kondom secara konsisten. Penggunaan PrEP dipromosikan secara luas pada komunitas laki-laki suka dengan laki-laki (LSL), termasuk LSL yang ingin mempraktekkan seks yang lebih aman pada hubungan seksual dengan pasangan tidak tetap yang sulit berbagi status HIV dan infeksi menular seksual (IMS) pada pasangan seksual tersebut. Namun, oleh karena praktik penggunaan kondom yang tidak konsisten saat menggunakan PrEP, terdapat dampak yang timbul yaitu adanya peningkatan kejadian infeksi menular seksual lainnya. Selain adanya transmisi penyakit terutama infeksi bakteri yang meningkat, penggunaan PrEP ternyata juga memiliki dampak efek protektif terhadap herpes simplex virus (HSV). Tinjauan pustaka ini membahas mengenai PrEP dan dampaknya pada infeksi menular seksual.


  1. WHO. WHO Implementation tool for pre-exposure prophylaxis (PrEP) of HIV infection. World Health Organization. 2017. 1–28 p.
  2. Aubin F, Vanhaecke C, Drobacheff C, Pelletier F. Pre-exposure Prophylaxis (PrEP) for HIV Infection and New Sexually Transmitted Infections: A Win-Win Opportunity? J AIDS HIV Treat. 2021;3(1):3–5.
  3. Centers for Disease Control and Prevention: U.S. Public Health Service. Preexoposure prophylaxis for the prevention of HIV infection in the United States – 2021 update [Internet]. 2021. 1–108 p. Available from:
  4. Lau JYC, Hung CT, Lee SS. A review of HIV pre-exposure prophylaxis (PrEP) programmes by delivery models in the Asia-Pacific through the healthcare accessibility framework. J Int AIDS Soc. 2020;23(7):14–6.
  5. Molina JM, Charreau I, Spire B, Cotte L, Chas J, Capitant C, et al. Efficacy, safety, and effect on sexual behaviour of on-demand pre-exposure prophylaxis for HIV in men who have sex with men: an observational cohort study. Lancet HIV. 2017;4(9):e402–10.
  6. Cazeau P, Jackson R, Theodore L, Balatien B. A literature review of issues affecting PrEP Education and Implementation in racism mistrust in black communities (HIV/AIDS). Integr Mol Med. 2017;4(1):1–4.
  7. Faini D, Munseri P, Sandstrom E, Hanson C, Bakari M. Awareness, Willingness and Use of HIV Pre-Exposure Prophylaxis Among Female Sex Workers Living in Dar-es-Salaam, Tanzania. AIDS Behav. 2022;1–9.
  8. Page M, Nicholls J. PrEP: pre-exposure prophylaxis for HIV prevention. Trends Urol Men’s Heal. 2018;9(4):22–4.
  9. Apers L, Vanhamel J, Caluwaerts S, Platteau T, Kenyon C, Florence E. Impact of PrEP on a STI clinic in a Belgian context: a provider’s perspective. Acta Clin Belgica Int J Clin Lab Med. 2021;76(6):477–81.
  10. Ndjoyi-Mbiguino A, Zoa-Assoumou S, Mourembou G, Ennaji MM. Human immunodeficiency virus: A brief review. Emerging and Reemerging Viral Pathogens: Volume 1: Fundamental and Basic Virology Aspects of Human, Animal and Plant Pathogens. Elsevier Inc.; 2019. 183–200 p.
  11. Dash PK, Kevadiya BD, Su H, Banoub MG, Gendelman HE. Pathways towards human immunodeficiency virus elimination. EBioMedicine. 2020;53:1–12.
  12. Aiken C, Rousso I. The HIV-1 capsid and reverse transcription. Retrovirology. 2021;18(1):1–9.
  13. Parekh BS, Ou CY, Fonjungo PN, Kalou MB, Rottinghaus E, Puren A, et al. Diagnosis of human immunodeficiency virus infection. Clin Microbiol Rev. 2019;32(1):1–55.
  14. Fanales-Belasio E, Raimondo M, Suligoi B, Butto S. HIV virology and pathogenetic mechanisms of infection: a brief overview. Ann Ist Super Sanità. 2010;476(1):5–14.
  15. Paim AC, Badley AD, Cummins NW. Mechanisms of Human Immunodeficiency Virus-Associated Lymphocyte Regulated Cell Death. AIDS Res Hum Retroviruses. 2020;36(2):101–15.
  16. Farshbaf A, Biglari A, Faghihzadeh S, Esmaeilzadeh A. Distribution of CCR5 Δ32 HIV-1 resistance allele frequency at Zanjan province in Iran. Immunopathol Persa. 2021;7(2):e26–e26.
  17. Maartens G, Celum C, Lewin SR. HIV infection: Epidemiology, pathogenesis, treatment, and prevention. Lancet. 2014;384(9939):258–71.
  18. Kemnic T, Gulick P. HIV Antiretroviral Therapy. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022. p. 1–64. Available from:
  19. Cunha RF, Simões S, Carvalheiro M, Azevedo Pereira JM, Costa Q, Ascenso A. Novel antiretroviral therapeutic strategies for HIV. Molecules. 2021;26(17):1–19.
  20. Luis H, Fridayantara WD, Mahariski P, Wignall FS, Irwanto I, Gedela K. Evolving ART crisis for people living with HIV in Indonesia. Lancet HIV. 2020;7(6):e384–5. Available from:
  21. Center for Disease Control and Prevention (CDC). Division of HIV Prevention Strategic Plan Supplement An Overview of Refreshed Priorities for 2022 – 2025 Table of Contents. United States: CDC; 2022. 1–22 p.
  22. Beymer M, Holloway I, Pulsipher C, Landovitz R. Current and Future PrEP Medications and Modalities: On Demand, Injectables, and Topicals. Curr HIV/AIDS Rep. 2019;16(4):349–58.
  23. Scott HM, Klausner JD. Sexually transmitted infections and pre-exposure prophylaxis: Challenges and opportunities among men who have sex with men in the US. AIDS Res Ther. 2016;13(1):1–5.
  24. Wulandari LPL, He SY, Fairley CK, Bavinton BR, Marie-Schmidt H, Wiseman V, et al. Preferences for pre-exposure prophylaxis for HIV: A systematic review of discrete choice experiments. eClinicalMedicine. 2022;51:101507.
  25. Traeger MW, Schroeder SE, Wright EJ, Hellard ME, Cornelisse VJ, Doyle JS, et al. Effects of Pre-exposure Prophylaxis for the Prevention of Human Immunodeficiency Virus Infection on Sexual Risk Behavior in Men Who Have Sex with Men: A Systematic Review and Meta-analysis. Clin Infect Dis. 2018;67(5):676–86.
  26. Baeten J, Donnel D, Mugo N, Ndase P, Thomas K, Campbell J, et al. Single-Agent Tenofovir versus Combination Emtricitabine/ Tenofovir for Pre-Exposure Prophylaxis against HIV-1 Acquisition: A Randomized Trial. Lancet Infect Dis. 2015;14(11):42–7.
  27. Fonner VA, Dalglish SL, Kennedy CE, Baggaley R, O’Reilly KR, Koechlin FM, et al. Effectiveness and safety of oral HIV preexposure prophylaxis for all populations. Aids. 2016;30(12):1973–83.
  28. Cempaka R, Wardhani B, Sawitri AAS, Januraga PP, Bavinton B. PrEP use awareness and interest cascade among msm and transgender women living in Bali, Indonesia. Trop Med Infect Dis. 2020;5(4):1–12.
  29. Omerhi I, Burks L. Impact of Pre-exposure Prophylaxis (PrEP) on sexually transmitted infection (STI) incidence among men who have sex with men (MSM) in Mecklenburg County North Carolina. Res Sq. 2022;1–14.
  30. Moreira J, Vasconcelos R, Doi A, Avelino-Silva V. Real-life occurrence of bacterial sexually transmitted infections among PrEP users: improving the diagnosis of Chlamydia trachomatis and Neisseria gonorrhoeae with multisite screening. J Sao Paulo Inst Trop Med. 2021;63:1–9.
  31. Traeger MW, Guy R, Asselin J, Patel P, Carter A, Wright EJ, et al. Real-world trends in incidence of bacterial sexually transmissible infections among gay and bisexual men using HIV pre-exposure prophylaxis (PrEP) in Australia following nationwide PrEP implementation: an analysis of sentinel surveillance data. Lancet Infect Dis. 2022;22(8):1231–41.
  32. Marcus JL, Glidden D V., McMahan V, Lama JR, Mayer KH, Liu AY, et al. Daily oral emtricitabine/tenofovir preexposure prophylaxis and herpes simplex virus type 2 among men who have sex with men. PLoS One. 2014;9(3):1–8.
  33. Andrei G, Lisco A, Vanpoullie C, Introini A, Balestra E, van den Oord J, et al. Topical Tenofovir, A Microbicide Effective Against HIV, Inhibits herpes Simplex Virus-2 Replication. Cell Host Microbe. 2011;10(4):379–89.
  34. Celum C, Morrow RA, Donnell D, Hong T, Hendrix CW, Thomas KK, et al. Daily oral tenofovir and emtricitabine-tenofovir preexposure prophylaxis reduces herpes simplex virus type 2 acquisition among heterosexual HIV-1-uninfected men and women: A subgroup analysis of a randomized trial. Ann Intern Med. 2014;161(1):11–9.
  35. Chaix ML, Charreau I, Pintado C, Delaugerre C, Mahjoub N, Cotte L, et al. Effect of on-demand oral preexposure prophylaxis with tenofovir/emtricitabine on herpes simplex virus-1/2 incidence among men who have sex with men: A substudy of the ANRS IPERGAY trial. Open Forum Infect Dis. 2018;5(11):1–5.
  36. Marrazzo JM, Rabe L, Kelly C, Richardson B, Deal C, Schwartz JL, et al. Tenofovir gel for prevention of herpes simplex virus type 2 acquisition: Findings from the VOICE trial. J Infect Dis. 2019;219(12):1940–7.
  37. Marrazzo JM, Dombrowski JC, Mayer KH. Sexually transmitted infections in the era of antiretroviral-based HIV prevention: Priorities for discovery research, implementation science, and community involvement. PLoS Med. 2018;15(1):3–8.

How to Cite

Mahariski, P. A., Puspawati, N. M. D., Indira, I. G. A. A. E., Praharsini, I. G. A. A., & Permana, A. (2023). Pre-exposure prophylaxis (PrEP) pada pencegahan human immunodeficiency virus (HIV) dan dampaknya terhadap infeksi menular seksual. Intisari Sains Medis, 14(2), 730–738.




Search Panel

Pande Agung Mahariski
Google Scholar
ISM Journal

Ni Made Dwi Puspawati
Google Scholar
ISM Journal

I Gusti Ayu Agung Elis Indira
Google Scholar
ISM Journal

I Gusti Ayu Agung Praharsini
Google Scholar
ISM Journal

Aditya Permana
Google Scholar
ISM Journal